Compare TRVG & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRVG | ENGN |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Germany | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.6M | 117.2M |
| IPO Year | 2015 | 2023 |
| Metric | TRVG | ENGN |
|---|---|---|
| Price | $5.65 | $1.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.95 | ★ $21.08 |
| AVG Volume (30 Days) | 162.1K | ★ 749.8K |
| Earning Date | 05-05-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $1.40 |
| 52 Week High | $6.49 | $12.25 |
| Indicator | TRVG | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 44.66 |
| Support Level | $2.76 | $1.67 |
| Resistance Level | $5.77 | $1.84 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 45.67 | 5.00 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.